Analysis of 1st quarter results:
Dr Reddy's said its growth in North America was largely driven by new product launches of clopidogrel, over-the-counter lansoprazole, and was further supported by key products like ziprasidone, fondaparinux, quetiapine, etc, marginally offset by regular year-on-year price declines in existing product basket.
http://www.moneycontrol.com/news/results/dr-reddys-labs-q1-disappoints-net28-at-rs-336-cr_732637.html
- Forums
- ASX - By Stock
- TSN
- dr. reddys
dr. reddys, page-27
Featured News
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online